Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA*...
Clinical Trial
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August...
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients- Dermata continues...
Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report
JERSEY CITY, N.J. , Aug. 7, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report...
DCN Dx to Showcase New Technologies at NextGen Dx 2024
Discover the Advanced miniDxR Customizable Lateral Flow Reader and Comprehensive CDMO and CRO Services at Booth 30 CARLSBAD, Calif, Aug....
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during...
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baselineCNM-Au8 treated...
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET)2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total...
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
CarnoSyn® Brands Unveils TriBsyn™ – “The World’s First Paresthesia-Free Beta-Alanine Powder”
CARLSBAD, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Exclusively from Natural Alternatives International, Inc. (NAI), CarnoSyn® Brands portfolio of patented...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint...
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3...
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a...
Ocular Therapeutix™ Reports Second Quarter 2024 Results
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate...
Velocity appoints ICON exec Rachael Buck Ph.D. as Head of U.K.
Rachael Buck Ph. D, Velocity UK Country Head Rachael Buck Ph. D, Velocity UK Country Head DURHAM, N.C., Aug. 07,...
Y-mAbs to Participate in Upcoming Investor Conferences in August
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives;...